Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Amplia Enters into Preclinical Collaboration with Korean Specialist Drug Screening Company Next&Bio
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
ASX Briefs podcast | Interview with Dr Chris Burns
Recruitment Restarts in Accent Pancreatic Cancer Trial
NBN News Interview
Categories
Archive
Company News
Investor Newsletters
Videos
14 Nov 2024
Amplia Enters into Preclinical Collaboration with Korean Specialist Drug Screening Company Next&Bio
Read More
30 Oct 2024
Interim Data from ACCENT Pancreatic Cancer Trial
Read More
28 Oct 2024
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
Read More
17 Oct 2024
ASX Briefs podcast | Interview with Dr Chris Burns
Read More
16 Oct 2024
Recruitment Restarts in Accent Pancreatic Cancer Trial
Read More
15 Oct 2024
NBN News Interview
Read More
09 Oct 2024
Dr Chris Burns Announced as Co-Recipient of 2024 Prime Minister's Prize for Innovation
Read More
27 Sep 2024
Bulls ‘n Bears interview with Dr Chris Burns
Read More
23 Sep 2024
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial
Read More
20 Sep 2024
FDA Fast Track Designation Granted to Narmafotinib in Pancreatic Cancer
Read More
12 Sep 2024
Investor Newsletter | September 2024
Read More
22 Aug 2024
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Read More
21 Aug 2024
Fifth partial response confirmed in ACCENT trial
Read More
12 Aug 2024
Amplia receives R&D Tax Rebate
Read More
07 Aug 2024
Key chemical form patents in Europe and Japan
Read More
06 Aug 2024
Fourth partial response confirmed in ACCENT trial
Read More
02 Aug 2024
ASX Briefs podcast | Interview with Dr Chris Burns
Read More
25 Jul 2024
Three confirmed partial responses observed in Phase 2a ACCENT trial
Read More
11 Jul 2024
JustStocks Feature Article and Video Interview with Amplia CEO Dr Chris Burns
Read More
03 Jul 2024
Recruitment of first 26 patients of Phase 2A ACCENT Trial now complete
Read More
1
2
3
4
5
6
